SMMT insider grant: 50,000 options to Chief Accounting Officer

Rhea-AI Filing Summary

Summit Therapeutics Inc. filed a Form 4 disclosing an equity award to Anand Bhaskar, the company's Chief Accounting Officer. On 09/18/2025 Mr. Bhaskar was granted a stock option to purchase 50,000 shares of common stock at an exercise price of $19.23 per share.

The option vests in four equal annual installments with the first vesting on 09/18/2026 and expires on 09/18/2035. After the grant, Mr. Bhaskar beneficially owns 50,000 underlying shares directly. The Form 4 was signed on 09/19/2025.

Positive

• Alignment of interests: Option grant ties the Chief Accounting Officer's compensation to future stock performance via a market-priced exercise at $19.23.
• Retention incentive: Four equal annual vesting installments beginning 09/18/2026 encourage multi-year tenure.

Negative

• Potential dilution: Grant represents 50,000 underlying shares; dilution impact cannot be assessed from this filing alone.
• No context on aggregate equity: Filing provides no information on total outstanding shares or company-wide option pool to gauge materiality.

Insights

Financial Analyst

TL;DR: A routine executive option grant of 50,000 shares at $19.23 aligns compensation with share performance and is a standard retention tool.

The grant to the Chief Accounting Officer is typical for executive compensation and ties a portion of pay to future stock appreciation. The four-year annual vesting schedule incentivizes retention through 2029. The exercise price equals the grant-date price, indicating no immediate intrinsic value. For investors, this is a routine disclosure with limited immediate financial impact absent context on total share count or outstanding dilution.

Corporate Governance Expert

TL;DR: Standard equity-based retention award with multi-year vesting; raises routine governance questions about pay alignment and dilution.

This Form 4 documents a standard option grant structure: multi-year vesting and a ten-year term. It reflects common practice to align senior finance officers with long-term shareholder interests. Materiality depends on the option size relative to total outstanding shares and existing incentive plans, information not provided in this filing. Without that context, this remains a typical governance disclosure rather than a material event.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Anand Bhaskar

(Last) (First) (Middle)

C/O SUMMIT THERAPEUTICS INC.

601 BRICKELL KEY DRIVE, SUITE 1000

(Street)

MIAMI FL 33131

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Summit Therapeutics Inc. [ SMMT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$19.23	09/18/2025		A		50,000		(1)	09/18/2035	Common Stock	50,000	(2)	50,000	D

Explanation of Responses:

1. The option was granted on September 18, 2025. The shares underlying the option shall vest in four equal annual installments, with the first such installment occurring on September 18, 2026.

2. Not applicable.

Remarks:

	/s/ Bhaskar Anand	09/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Summit Therapeutics (SMMT) disclose on this Form 4?

The company disclosed a grant of a stock option to Chief Accounting Officer Anand Bhaskar for 50,000 shares at an exercise price of $19.23 dated 09/18/2025.

When do the awarded options to Anand Bhaskar begin to vest?

The option vests in four equal annual installments with the first vesting on 09/18/2026.

What is the expiration date of the options granted to the reporting person?

The options expire on 09/18/2035.

How many shares does Anand Bhaskar beneficially own following the reported transaction?

Following the grant, the Form 4 reports beneficial ownership of 50,000 underlying shares.

Was the Form 4 signed and when?

Yes. The Form 4 bears the signature of Anand Bhaskar dated 09/19/2025.